Cargando...
Differentiating mTOR Inhibitors in Renal Cell Carcinoma
PI3K/Akt/mTOR signalling is dysregulated in many cancers, including renal cell carcinoma (RCC), and activation of this pathway has been suggested to correlate with aggressive behavior and poor prognosis in RCC tumors. mTOR inhibition plays a principal role in the targeted treatment of many cancer ty...
Gardado en:
| Publicado en: | Cancer Treat Rev |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2013
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4957946/ https://ncbi.nlm.nih.gov/pubmed/23433636 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ctrv.2012.12.015 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|